Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604514 | 0.80 | SLC6A11 (0.49) | SLC6A1SLC6A11KIF11CYP2C9ALOX15 | |
| SCHEMBL5604595 | 0.80 | SLC6A11 (0.49) | SLC6A1SLC6A11KIF11CYP2C9ALOX15 | |
| SCHEMBL5967855 | 0.80 | SLC6A11 (0.49) | SLC6A1SLC6A11KIF11CYP2C9ALOX15 | |
| SCHEMBL8633174 | 0.80 | KIF11 (0.48) | SLC6A1SLC6A11KIF11 | |
| SCHEMBL3690284 | 0.79 | KIF11 (0.50) | SLC6A1SLC6A11KIF11 | |
| SCHEMBL3693004 | 0.77 | CA1 (0.46) | TSHR | |
| SCHEMBL26404692 | 0.76 | SLC6A11 (0.48) | SLC6A1SLC6A11KIF11CYP2C9ALOX15 | |
| SCHEMBL26404634 | 0.76 | SLC6A11 (0.48) | SLC6A1SLC6A11KIF11CYP2C9ALOX15 | |
| SCHEMBL4424977 | 0.76 | KIF11 (0.43) | KIF11AOC3SLC6A2SLC6A4 | |
| SCHEMBL3695302 | 0.76 | SLC6A11 (0.48) | SLC6A1SLC6A11KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2064223-B1 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | DHARMACON, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8252755-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | SNRPE, DCLRE1B, RNASE1 | SLC6A1 3955/4885SLC6A11 4048/4885KIF11 1907/4885 |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | SNRPE, AGO2, DCLRE1B | SLC6A1 4432/4885SLC6A11 4459/4885KIF11 2025/4885 |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | SRRT, SNRPE, SSBP1 | SLC6A1 4057/4885SLC6A11 4167/4885KIF11 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.